A brand new analysis perspective was revealed in Oncoscience (Quantity 11) on February 7, 2024, entitled, “IPIAD- an augmentation routine added to straightforward remedy of pancreatic ductal adenocarcinoma utilizing already-marketed repurposed medicine irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone.”
On this new paper, researcher Richard E. Kast from IIAIGC Research Middle presents the information and rationale for including 5 generic non-oncology medicine from common medical apply to gemcitabine, nab-paclitaxel, a present customary cytotoxic chemotherapy of pancreatic ductal adenocarcinoma. The routine, referred to as IPIAD, makes use of an angiotensin receptor blocker (ARB) irbesartan indicated for treating hypertension, an previous antimicrobial drug pyrimethamine indicated for treating toxoplasmosis or malaria, an previous antifungal drug itraconazole, an previous broad spectrum antibiotic azithromycin, and an previous antibiotic dapsone.
“In reviewing chosen progress driving methods lively in pancreatic ductal adenocarcinoma then evaluating these with detailed knowledge on ancillary attributes of the IPIAD medicine, one can predict scientific profit and slowing progress of pancreatic ductal adenocarcinoma by this augmentation routine.”
Kast, R. E. (2024). IPIAD- an augmentation routine added to straightforward remedy of pancreatic ductal adenocarcinoma utilizing already-marketed repurposed medicine irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone. Oncoscience. doi.org/10.18632/oncoscience.594.